Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN phase 3 trial of brensocatib in non-cystic fibrosis bronchiectasis
MOH_2020-11-04_009479Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brensocatib in bronchiectasis (3 arms), sponsored by Insmed Incorporated. Primary endpoint: Rate of pulmonary exacerbations during 52-week treatment period. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on MOH_2020-11-04_009479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-04_009479.